RPC1063

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2016
01220142016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the… (More)
Is this relevant?
Review
2017
Review
2017
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, involve an inappropriate immune reaction in… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… (More)
  • figure 1
  • figure 2
  • table 1
  • table 3
Is this relevant?
2016
2016
BACKGROUND AND PURPOSE Sphingosine1-phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac… (More)
  • figure 2
  • figure 1
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Review
2015
Review
2015
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… (More)
Is this relevant?
2015
2015
In its third major acquisition in 3 months, Celgene is buying the biotech company Receptos for US$7.2 billion. In doing so… (More)
Is this relevant?
Review
2015
Review
2015
antiviral agents, many patients face barriers to access. In our Advances in Hepatology column, Dr David E. Bernstein discusses… (More)
Is this relevant?
2015
2015
therapy for Crohn’s disease. N Engl J Med 2005; 353:362–368. 6. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction… (More)
  • figure 1
Is this relevant?
2014
2014
Background: RPC1063 is an oral, selective sphingosine 1-phosphate 1 receptor modulator in clinical development for the treatment… (More)
Is this relevant?